India · Delayed Price · Currency is INR Ion Exchange (India) Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 saw 20% revenue growth but a 49% EBITDA decline, with profitability impacted by legacy projects and input costs. New segment reporting, capacity expansions, and a strong order pipeline position the company for improved margins as legacy issues resolve and international growth accelerates.
Fiscal Year 2026
-
Q4 and FY26 saw modest revenue growth but margin pressure from input cost inflation and West Asia disruptions. Engineering and chemical segments faced headwinds, while consumer products grew strongly. Strategic partnerships and new certifications support long-term growth.
-
Q3 saw modest revenue growth but lower margins due to project mix, Roha ramp-up, and higher costs. Order inflow remains strong, with improved profitability expected as legacy projects taper and Roha scales up. Consumer products and services segments are showing robust growth.
-
Q2 and H1 FY26 saw revenue growth across all segments, with engineering margins impacted by legacy projects and infra costs, while chemical and consumer divisions showed strong performance. The Roha plant was commissioned, and a strategic membrane partnership was announced. Order inflow and bid pipeline remain robust.
-
Q1 FY26 saw 3% revenue growth and 8% net profit rise, despite SAP transition challenges and lower chemical/engineering revenues. Roha plant commissioning is on track to boost exports, while consumer products posted strong growth. Engineering margins benefited from a one-time item.
Fiscal Year 2025
-
Operating income and net profit grew year-on-year, but Q4 margins were pressured by legacy projects and slow execution in the engineering segment. The chemical division showed strong volume growth, with the new Roha plant set to drive future expansion. Order inflow is expected to improve as delayed opportunities materialize.
-
Q3 and nine-month results showed strong revenue and profit growth, with engineering and chemical segments performing well. Margins are impacted by a legacy contract and slow government project execution, but growth guidance remains robust at 15%-20% for FY25.
-
Q2 and H1 FY25 saw strong double-digit revenue and profit growth, with robust order inflows and a healthy pipeline across engineering and chemicals. Margin improvement is constrained by a one-off contract, but H2 is expected to outperform H1, supported by new capacity and international expansion.
-
Q1 FY25 saw strong year-over-year growth in revenue, EBITDA, and net profit, with robust performance in both engineering and chemical segments. Execution of large contracts is expected to accelerate, and management transition to professional leadership is planned for October 2024.